Roth MKM Reiterates Buy on Fortress Biotech, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jason Wittes has reiterated a Buy rating on Fortress Biotech (NASDAQ:FBIO) and maintained a $10 price target.
May 16, 2024 | 5:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roth MKM analyst Jason Wittes has reiterated a Buy rating on Fortress Biotech and maintained a $10 price target.
The reiteration of a Buy rating and the maintenance of a $10 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100